Overview
At Nanotreat Inc., our research is focused on leveraging the latest advancements in nanotechnology to develop effective treatments against airborne pathogens. Our core research areas are designed to address some of the most pressing challenges in healthcare today, with a particular emphasis on preventing and treating viral infections like SARS-CoV-2.
LNP-Based Inhibitors
Overview: Lipid Nanoparticles (LNPs) are at the heart of our therapeutic innovations. Our LNP-based inhibitors are engineered to neutralize viruses in the nasal cavity, providing a frontline defense against airborne pathogens. These inhibitors are specifically designed to target and trap viruses, preventing them from binding to and entering host cells.
Key Projects:
LNP-Trap: A novel formulation that binds to the viral spike protein, effectively neutralizing the virus before it can infect cells. This approach not only inhibits the virus but also reduces the risk of transmission.
LNP-Trim: This formulation delivers siRNA to host cells to knock down key receptors, such as ACE2 and TMPRSS2, that viruses use to gain entry into the body. By targeting these receptors, LNP-Trim reduces the ability of viruses to infect cells, offering a powerful tool in the fight against viral infections.
Impact: Our LNP-based inhibitors have shown significant potential in preclinical studies, demonstrating the ability to reduce viral load and prevent infection. This research area is central to our efforts to develop next-generation treatments that are both effective and easy to administer.
Gene Knockdown Therapies
Overview: Gene knockdown technology involves silencing specific genes to prevent the production of proteins that are essential for viral replication. At Nanotreat, we utilize RNA interference (RNAi) technology to achieve this, delivering small interfering RNA (siRNA) directly to target cells using our LNP delivery system.
Key Projects:
siRNA Delivery via LNP-Trim: Our research focuses on the targeted delivery of siRNA using LNP-Trim technology to knock down the expression of ACE2 and TMPRSS2, the key receptors SARS-CoV-2 uses to enter human cells. By reducing the expression of these receptors, we aim to significantly lower the risk of infection and limit the spread of the virus within the body.
Impact: The ability to selectively target and silence genes crucial to viral entry represents a powerful therapeutic strategy. Our gene knockdown therapies not only have the potential to complement existing treatments but also offer an additional layer of protection against emerging viral threats, enhancing our overall defense against infectious diseases.
MON – FRI 9AM-5PM CST
Sales | Support | Investor Relations
info@nanotreat.ca
Need help? send an e-mail
+1(431)222-3009
Any questions? Reach Us Anytime